Search results
Showing 391 to 405 of 1373 results for social care
In development Reference number: GID-TA11495 Expected publication date: 18 March 2026
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]
In development Reference number: GID-TA11651 Expected publication date: 04 June 2026
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]
In development Reference number: GID-TA11678 Expected publication date: 19 August 2026
In development Reference number: GID-TA11774 Expected publication date: 30 September 2026
In development Reference number: GID-TA10726 Expected publication date: 25 February 2026
In development Reference number: GID-TA11379 Expected publication date: TBC
In development Reference number: GID-TA11115 Expected publication date: TBC
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.
View quality statements for QS99Show all sections
Sections for QS99
- Quality statements
- Quality statement 1: Assessment of left ventricular function
- Quality statement 2: Referral for cardiac rehabilitation
- Quality statement 3: Communication with primary care
- Quality statement 4: Cardiac rehabilitation – assessment appointment
- Quality statement 5 (developmental): Options for cardiac rehabilitation
- Update information
- About this quality standard
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development Reference number: GID-TA10994 Expected publication date: TBC
This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [TSID11905] [ID6529]
Awaiting development Reference number: GID-TA11414 Expected publication date: TBC
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]
In development Reference number: GID-HST10063 Expected publication date: TBC
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]
In development Reference number: GID-TA11561 Expected publication date: 01 April 2026